Ligand director exercises options, sells shares
Ligand Pharmaceuticals director Jason Haas reported an option exercise and share sale dated August 12, 2026.
Rhea-AI Filing Summary
Ligand Pharmaceuticals director Jason Haas reported an option exercise and share sale dated August 12, 2026. He exercised a Non-Qualified Stock Option for 6,138 shares of common stock at an exercise price of $51.56 per share, fully disposing of this option grant. He then reported acquiring 6,138 common shares from the exercise and selling 7,138 common shares at a weighted-average price of $292.8078 per share, with individual sale prices ranging from $292.5000 to $292.8550. The Rule 10b5-1 trading-plan checkbox was not marked for these transactions.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Haas Jason
Role
Director
Sold
7,138 shs ($2.09M)
Approx. gross sale proceeds
$2.09M
Approx. exercise cost
$316K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F2 | 6,138 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,138 | $51.56 | $316K |
| Sale | Common Stock F1 | 7,138 | $292.8078 | $2.09M |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 3,981 shares (Direct)
Footnotes (2)
- F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Key Figures
Options Exercised: 6,138 shares
Option Exercise Price: $51.56 per share
Shares Sold: 7,138 shares
+4 more
7 metrics
Options Exercised
6,138 shares
Non-Qualified Stock Option converted into common stock on August 12, 2026
Option Exercise Price
$51.56 per share
Exercise price for the 6,138-share Non-Qualified Stock Option
Shares Sold
7,138 shares
Common stock sale reported on August 12, 2026
Weighted-Average Sale Price
$292.8078 per share
Weighted-average price for the 7,138 Ligand shares sold
Sale Price Range
$292.5000 to $292.8550 per share
Range of individual sale prices for the reported transactions
Original Option Grant
5,907 shares at $88.48 per share
Initial terms of the option before adjustment for OmniAb Inc. separation
Option Expiration Date
June 29, 2032
Expiration date of the Non-Qualified Stock Option that was exercised
Key Terms
Non-Qualified Stock Option, weighted-average price, Rule 10b5-1, OmniAb Inc. separation
4 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Rule 10b5-1 financial
"The Rule 10b5-1 trading-plan checkbox was not marked for these transactions."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
OmniAb Inc. separation financial
"but was adjusted pursuant to the OmniAb Inc. separation from the issuer."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ligand Pharmaceuticals (LGND) director Jason Haas report in this Form 4?
Jason Haas reported exercising options for 6,138 shares of Ligand Pharmaceuticals common stock at $51.56 per share and selling 7,138 shares on August 12, 2026, at a weighted-average price of $292.8078 per share.
What stock option did Jason Haas exercise in the Ligand (LGND) Form 4?
He exercised a Non-Qualified Stock Option covering 6,138 shares of Ligand common stock at an exercise price of $51.56 per share. The option, expiring June 29, 2032, was fully disposed in this transaction.
What historical details were disclosed about Jason Haas’s Ligand (LGND) option grant?
A footnote states the option was originally reported as a grant of 5,907 shares on June 29, 2022 at an exercise price of $88.48 per share and was adjusted in connection with the OmniAb Inc. separation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
